Lusutrombopag: Complete Guide to Dosage, Administration and Clinical Monitoring

　　Lusutrombopag is an oral therapeutic agent for thrombocytopenia in patients with chronic liver disease.Its core clinical role is to raise platelet counts to support the safe performance of elective invasive procedures.

　　Standard Dosage and Administration

　　The recommended dose of lusutrombopag is 3 mg taken orally once daily,with a full treatment course lasting 7 consecutive days.The course should be initiated 8 to 14 days before the scheduled invasive procedure to ensure platelet levels rise to an appropriate range prior to the procedure.Drug absorption is not affected by food;patients may take it with or without meals.It is recommended to take the medication at a fixed time every day to maintain stable plasma drug concentration and consistent therapeutic effect.

　　Dose Adjustment Principles

　　In routine clinical practice,no dose adjustment of lusutrombopag is required based on patients'baseline physical status.Patients with renal impairment or hepatic impairment,as well as elderly populations,may use the standard recommended dose without additional reduction.Only in special monitoring scenarios,if the patient's platelet count rises too rapidly(exceeding 200×10^9/L)during treatment,the attending physician may consider early discontinuation after evaluation.The overall risk of this occurrence is low,and routine preventive dose adjustment is not required.

　　Missed Dose Management

　　If a patient misses a single dose,the management should be determined based on the time remaining until the next scheduled dose:if the missed dose is remembered more than 8 hours before the next scheduled dose,the missed dose should be taken immediately.If less than 8 hours remain before the next scheduled dose,the missed dose should be skipped,and the regular dosing schedule should be resumed the next day.It is strictly prohibited to take a double dose to make up for a missed dose,to avoid potential risks such as excessive platelet elevation.

　　Monitoring Requirements During Treatment

　　Baseline platelet count should be measured before initiating treatment as a reference for subsequent efficacy evaluation.During treatment,platelet count should be rechecked on day 4 and day 7 of administration to dynamically assess the platelet-raising effect.If the patient's platelet count remains below 50×10^9/L after completing the 7-day standard course,the clinician may evaluate whether to extend the course to 10 to 14 days based on the patient's individual condition and procedural needs.This extended use falls under off-label medication,and must be implemented by a professional physician after fully weighing the benefits and risks.

　　Discontinuation and Procedure Timing

　　After completing the 7-day standard course and discontinuing the drug,the patient's platelet count usually peaks 2 to 5 days after the last dose.It is clinically recommended to schedule the elective invasive procedure within 5 to 9 days after the last dose to ensure platelets remain at a safe and appropriate level during the procedure.If the procedure is delayed for special reasons,a full treatment course may be restarted,but an interval of at least 2 weeks is required between two courses to avoid health risks caused by excessive platelet elevation.

　　Special Population Considerations

　　The safety and efficacy of lusutrombopag in pediatric populations have not been fully verified,and routine use in pediatric patients is not recommended.For pregnant women,existing animal studies have not found clear teratogenic effects,but sufficient human clinical data are still lacking.Clinical use should be decided by physicians after carefully evaluating the benefits and potential risks.